Departamento de Producción Agrícola y Animal, Universidad Autónoma Metropolitana , Mexico City , México.
Department of Poultry Science, University of Arkansas , Fayetteville, AR , USA.
Front Vet Sci. 2016 Aug 31;3:72. doi: 10.3389/fvets.2016.00072. eCollection 2016.
The objectives of the present study were to evaluate the risks involved in the use of Enrofloxacin for Salmonella Enteritidis (SE) or Salmonella Heidelberg (SH) in commercial poultry and determine the effects of a probiotic as an antibiotic alternative. Two experiments were conducted to evaluate the risks involved in the use of Enrofloxacin for SE or SH in commercial poultry. Experiment 1 consisted of two trials. In each trial, chickens were assigned to one of three groups; control + SE challenged; Enrofloxacin 25 mg/kg + SE; and Enrofloxacin 50 mg/kg + SE. Chickens received Enrofloxacin in the drinking water from days 1 to 5 of age. On day 6, all groups received fresh water without any treatment. All chickens were orally gavaged with 10(7) cfu/chick of SE at 7 days of age and euthanized on 8 days of age. In Experiment 2, turkey poults were assigned to one of the three groups; control + SH; probiotic + SH; and Enrofloxacin 50 mg/kg + SH. Poults received probiotic or Enrofloxacin in the drinking water from days 1 to 5 of age. On day 6, poults received fresh water without any treatment. Poults were orally gavaged with 10(7) cfu/poult of SH at 7 days of age. Poults were weighed and humanely killed 24 h post-SH challenge to evaluate serum concentration of fluorescein isothiocyanate-dextran to evaluate intestinal permeability, metagenomics, and SH infection. In both trials of Experiment 1, chickens treated with Enrofloxacin were more susceptible to SE organ invasion and intestinal colonization when compared with control non-treated chickens (P < 0.05). In Experiment 2, poults treated with 50 mg/kg of Enrofloxacin showed an increase in body weight, however, this group also showed an increase in SH susceptibility, intestinal permeability, and lower proportion of Firmicutes and Bacteroidetes, but with control group had the highest proportion of Proteobacteria. By contrast, poults that received the probiotic had the highest proportion of Firmicutes and Bacteroidetes, but lowest Proteobacteria. The results of the present study suggest that prophylactic utilization of Enrofloxacin at five times the recommended dose in poultry increases the susceptibility to salmonellae infections, and confirms that probiotics may be an effective tool in salmonellae infections.
本研究的目的是评估在商业家禽中使用恩诺沙星治疗肠炎沙门氏菌(SE)或海德堡沙门氏菌(SH)的风险,并确定益生菌作为抗生素替代品的效果。进行了两项实验来评估在商业家禽中使用恩诺沙星治疗 SE 或 SH 的风险。实验 1 包括两项试验。在每个试验中,鸡被分为三组之一;对照组+SE 攻毒;恩诺沙星 25mg/kg+SE;和恩诺沙星 50mg/kg+SE。鸡从 1 日龄到 5 日龄通过饮水摄入恩诺沙星。第 6 天,所有组均接受不含任何处理的新鲜水。所有鸡于 7 日龄时口服 10(7)cfu/只 SE,并于 8 日龄时安乐死。在实验 2 中,火鸡雏鸡被分为三组之一;对照组+SH;益生菌+SH;和恩诺沙星 50mg/kg+SH。雏鸡从 1 日龄到 5 日龄通过饮水摄入益生菌或恩诺沙星。第 6 天,雏鸡接受不含任何处理的新鲜水。7 日龄时,雏鸡口服 10(7)cfu/只 SH。24 小时后,雏鸡接受 SH 攻毒后进行称重和人道处死,以评估荧光素异硫氰酸酯-葡聚糖的血清浓度以评估肠道通透性、宏基因组学和 SH 感染。在实验 1 的两项试验中,与对照组非处理鸡相比,用恩诺沙星处理的鸡对 SE 器官侵袭和肠道定植更易感(P<0.05)。在实验 2 中,用 50mg/kg 恩诺沙星处理的雏鸡体重增加,但该组也显示出对 SH 的易感性增加、肠道通透性增加和变形菌门和拟杆菌门比例降低,但与对照组相比,变形菌门比例最高。相比之下,接受益生菌的雏鸡Firmicutes 和 Bacteroidetes 比例最高,但 Proteobacteria 比例最低。本研究结果表明,在家禽中预防性使用推荐剂量五倍的恩诺沙星会增加对沙门氏菌感染的易感性,并证实益生菌可能是沙门氏菌感染的有效工具。